Notice 25 Sep 2025 archaeology, native american, grave protection, repatriation, compliance, cultural heritage

⚰️Notice of Inventory Completion on Repatriation of Cultural Artifacts

In accordance with the Native American Graves Protection and Repatriation Act (NAGPRA), the Robert S. Peabody Institute of Archaeology (RSPI) has completed an inventory of human remains and associated funerary objects and has determined that there is a cultural affiliation between the human remains and associated funerary objects and Indian Tribes or Native Hawaiian organizations in this notice.

Learn More
Notice 25 Sep 2025 healthcare, regulation, medical devices, sterilization, compliance, fda

⚗️FDA Notice

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 25 Sep 2025 archaeology, repatriation, nagpra, maryland, compliance, nps, cultural heritage

🏺Notice of Inventory Completion by National Park Service

In accordance with the Native American Graves Protection and Repatriation Act, the U.S. Department of the Interior, National Park Service, Chesapeake and Ohio Canal National Historical Park (CHOH) has completed an inventory of human remains and has determined that there is a cultural affiliation between the human remains and Indian Tribes in this notice.

Learn More
Notice 25 Sep 2025 irs, real estate, business impact, compliance, mortgage investment conduits, financial regulation

🏠IRS Notice on Real Estate Mortgage Investment Conduits

In accordance with the Paperwork Reduction Act of 1995, the IRS is inviting comments on the information collection request outlined in this notice.

Learn More
Notice 25 Sep 2025 food safety, food facilities, health, regulation, bioterrorism, compliance, fda

🍽️FDA Notice on Food Facility Registration and Compliance Requirements

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 25 Sep 2025 federal regulation, u.s. marshals service, information collection, compliance, doj

📄Proposed Information Collection for Leased/Charter/Contract Personnel

The U.S. Marshals Service (USMS), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

Learn More
Notice 25 Sep 2025 clearing agencies, regulation, financial services, securities, compliance

📈SEC's Proposed Rule Changes Impacting Financial Clearing Agencies

The SEC has announced the designation of a longer period for reviewing proposed rule changes related to system disruptions by the Depository Trust Company, Fixed Income Clearing Corporation, and National Securities Clearing Corporation. Comments have been received, and the Commission emphasizes the need for sufficient time to evaluate the changes before approval or disapproval.

Learn More
Notice 25 Sep 2025 finance, regulation, sec, securities, compliance, business

📄SEC Review of Rule 12d1-3 Information Collection Request

The SEC announces the submission for OMB review for extension of Rule 12d1-3, which mandates certification for securities listing and registration. The notice details the estimated burden on respondents and highlights the public commentary opportunity for the information collection request.

Learn More
Notice 25 Sep 2025 health, regulation, harmful constituents, tobacco, compliance, fda

🚬FDA Notice on Reporting Harmful Constituents in Tobacco Products

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Learn More
Notice 25 Sep 2025 biotechnology, gene therapy, cell therapy, regulation, compliance, fda

🧬FDA Guidance on Postapproval Safety and Efficacy for CGT Products

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled "Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products; Draft Guidance for Industry." The draft guidance document discusses methods and approaches for capturing postapproval safety and efficacy data for cell and gene therapy (CGT) products. Given the potential for long-lasting effects of CGT products, and the generally limited number of participants treated in clinical trials, the collection of postapproval study data for CGT products is important for gathering data on product safety and effectiveness over time.

Learn More